

12, 19-02

1624



DOCKET NO.: CELL-0113

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Langham, Et Al.

Serial No.: 09/899,488

Filing Date: July 5, 2001

For: Squaric Acid Derivatives

Confirmation No.: 2595

Group Art Unit: 1624

Examiner: T.C. McKenzie

RECEIVED
DEC 23 2002
TECH CENTER 1600/2900

EXPRESS MAIL LABEL NO: EV 160091721 US
DATE OF DEPOSIT: December 18, 2002

EV160091721US

Box NON-FEE
 AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

REPLY TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- An Amendment Responsive to the Office Action Dated July 24, 2002.
- An Amendment Supplemental to the Paper filed
- Other:

- Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.
- Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:
 - an Independent Inventor
 - a Small Business Concern
 - a Nonprofit Organization
- This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.
- Loss of Entitlement Enclosed
- Substitute Pages _____ of the Specification are enclosed.
- An Abstract is enclosed.
- Sheets of Proposed Corrected Drawings are enclosed.
- A Certified Copy of each of the following applications: _____ is enclosed.
- An Associate Power of Attorney is enclosed.
- Information Disclosure Statement.
 - Attached Form 1449.
 - A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- Appended Material as follows: Appendix A, "Molecular Variations Based on Isosteric Replacements" (7 pages); Appendix B, Grant & Hachk's Chemical Dictionary (3 pages); Appendix C Grant & Hachk's Chemical Dictionary (3 pages); Appendix D, Drug Report from the Investigational Drugs Database (5 pages); Appendix E, Ch.. 7 "Targeting VLA-4 Integrin Function: Potential Therapeutic Implications (10 pages) Chapter 8 "Role of the Intergrin $\alpha 4\beta 1$ (VLA-4) in Inflammatory Disorders" (8 pages).
- Other Material as follows:

FEE CALCULATION

No Additional Fee is Due.

			SMALL ENTITY		NOT SMALL ENTITY		
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	Fee	RATE	Fee
TOTAL CLAIMS	26	26 (20 MINIMUM)	0	\$9 EACH	\$	\$18 EACH	\$0
INDEP. CLAIMS	2	3 (3 MINIMUM)	0	\$42 EACH	\$	\$84 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$	\$280	\$0
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$0
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$400.00
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$0
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$0
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$0
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$0)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$0
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							\$0
TOTAL FEE DUE					\$		\$400.00

- A check in the amount of \$400.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
- Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4) to extend the time for response to the Office Action of July 24, 2002 to and through December 24, 2002 comprising an extension of the shortened statutory period of two (2) month(s).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is provided in duplicate.
- The foregoing amount due for filing this paper.

- Any additional filing fees required, including fees for the presentation of extra claims under 37 CFR § 1.16.
- Any additional patent application processing fees under 37 CFR § 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: December 18, 2002

Jane Ingles
Jane E. Ingles
Registration No. 48,444

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2002 WW